South Korea
· Delayed Price · Currency is KRW HLB Pharmaceutical Statistics
Total Valuation
HLB Pharmaceutical has a market cap or net worth of KRW 377.74 billion.
| Market Cap | 377.74B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
HLB Pharmaceutical has 14.04 million shares outstanding.
| Shares Outstanding | 14.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.70% |
| Owned by Insiders (%) | 11.17% |
| Owned by Institutions (%) | 3.86% |
| Float | 8.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.32 |
| PB Ratio | 20.81 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 73.72.
| Current Ratio | 1.26 |
| Quick Ratio | 1.01 |
| Debt / Equity | 73.72 |
| Debt / EBITDA | 4.28 |
| Debt / FCF | -301.34 |
| Interest Coverage | 1.21 |
Financial Efficiency
Return on equity (ROE) is 2.71% and return on invested capital (ROIC) is 3.23%.
| Return on Equity (ROE) | 2.71% |
| Return on Assets (ROA) | 2.19% |
| Return on Capital (ROIC) | 3.23% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.88 |
| Inventory Turnover | 3.27 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +105.32% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +105.32% |
| 50-Day Moving Average | 26,893.00 |
| 200-Day Moving Average | 22,977.15 |
| Relative Strength Index (RSI) | 51.85 |
| Average Volume (20 Days) | 360,244 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB Pharmaceutical had revenue of KRW 36.10 billion and earned 472.66 million in profits. Earnings per share was 34.13.
| Revenue | 36.10B |
| Gross Profit | 18.04B |
| Operating Income | 1.44B |
| Pretax Income | -123.03M |
| Net Income | 472.66M |
| EBITDA | 3.08B |
| EBIT | 1.44B |
| Earnings Per Share (EPS) | 34.13 |
Balance Sheet
The company has 15.16 billion in cash and 13.20 billion in debt, giving a net cash position of 1.96 billion or 139.93 per share.
| Cash & Cash Equivalents | 15.16B |
| Total Debt | 13.20B |
| Net Cash | 1.96B |
| Net Cash Per Share | 139.93 |
| Equity (Book Value) | 17.90B |
| Book Value Per Share | 1,292.83 |
| Working Capital | 5.93B |
Cash Flow
In the last 12 months, operating cash flow was 1.35 billion and capital expenditures -1.40 billion, giving a free cash flow of -43.80 million.
| Operating Cash Flow | 1.35B |
| Capital Expenditures | -1.40B |
| Free Cash Flow | -43.80M |
| FCF Per Share | -3.12 |
Margins
Gross margin is 49.98%, with operating and profit margins of 3.99% and 1.31%.
| Gross Margin | 49.98% |
| Operating Margin | 3.99% |
| Pretax Margin | -0.34% |
| Profit Margin | 1.31% |
| EBITDA Margin | 8.53% |
| EBIT Margin | 3.99% |
| FCF Margin | -0.12% |
Dividends & Yields
HLB Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.30% |
| Shareholder Yield | -2.30% |
| Earnings Yield | 0.13% |
| FCF Yield | -0.01% |
Stock Splits
The last stock split was on April 12, 2016. It was a forward split with a ratio of 1.5.
| Last Split Date | Apr 12, 2016 |
| Split Type | Forward |
| Split Ratio | 1.5 |